Skip to main content
Cabio Biotech(Wuhan) Co., Ltd. logo

Cabio Biotech(Wuhan) Co., Ltd. — Investor Relations & Filings

Ticker · 688089 ISIN · CNE100005X31 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 750 across all filing types
Latest filing 2026-04-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688089

About Cabio Biotech(Wuhan) Co., Ltd.

https://www.cabio.com/

Cabio Biotech (Wuhan) Co., Ltd. specializes in the research, development, and large-scale production of high-quality nutritional chemicals and functional ingredients through advanced fermentation and bio-manufacturing processes. The company’s core product portfolio includes Arachidonic Acid (ARA), algal oil Docosahexaenoic Acid (DHA), Sialic Acid (N-acetylneuraminic acid), and Beta-carotene. These ingredients are primarily utilized in infant formula, dietary supplements, functional foods, and personal care products. Cabio focuses on providing sustainable, bio-based solutions to global manufacturers, adhering to international quality standards and regulatory requirements. By leveraging its expertise in microbial oil synthesis and precision fermentation, the company supports the development of health-oriented products across the human and animal nutrition sectors.

Recent filings

Filing Released Lang Actions
嘉必优生物技术（武汉）股份有限公司2025年度审计委员会关于会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 75% confidence The document is not an annual or interim financial statement; rather, it is a formal report by the Board’s Audit Committee on its oversight of the external auditor’s work. It does not announce management changes, dividends, or legal actions, nor is it a proxy or earnings release. It represents standalone audit-related information, detailing the committee’s supervision of the audit firm’s procedures and performance, which aligns with the definition of Audit Report / Information (AR).
2026-04-22 Chinese
嘉必优生物技术(武汉)股份有限公司关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Ms. Su Xiaohe, from the board of 嘉必优生物技术（武汉）股份有限公司. It details the resignation date, reasons, and the impact on the board composition. There is no financial data, audit information, or report content. The focus is on management changes specifically related to the board of directors. Therefore, this fits the category of Board/Management Information (MANG). The document length and content confirm it is not a report or announcement of a report but a direct management change notice.
2026-03-25 Chinese
嘉必优生物技术(武汉)股份有限公司关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Wang Yifei, from the board of 嘉必优生物技术（武汉）股份有限公司. It details the resignation date, reasons, and the impact on the board's composition. There is no financial data, audit information, or report content. The focus is on management changes, specifically a board member's departure. This fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2026-03-20 Chinese
嘉必优生物技术（武汉）股份有限公司2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025年度业绩快报公告" which translates to "2025 Annual Performance Express Announcement" or "2025 Annual Results Summary Announcement." It contains preliminary financial data for the year 2025, including revenue, profit, net assets, and earnings per share, but explicitly states that the data is preliminary and unaudited, and that the final audited data will be in the full annual report. The document is relatively short (1554 characters) and serves as a summary or quick announcement of the annual results rather than the full detailed annual report itself. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. It is not the full Annual Report (10-K), nor is it a report publication announcement (RPA) because it contains substantive financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER).
2026-02-27 Chinese
嘉必优生物技术（武汉）股份有限公司关于第二期股份回购实施结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 嘉必优生物技术（武汉）股份有限公司 regarding the implementation results of their second phase share repurchase program and the resulting changes in shareholding. It details the number of shares repurchased, prices, approvals, and future plans for the repurchased shares. The document includes specific data on shares bought back, prices, and the impact on share capital. It is not a full financial report, earnings release, or management discussion, but a formal disclosure of share repurchase activity and shareholding changes. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on company buybacks or sales of its own shares.
2026-01-26 Chinese
嘉必优生物技术（武汉）股份有限公司关于第二期以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's second phase of share repurchase through centralized bidding. It includes details such as the number of shares repurchased, the price range, total amount spent, and references to previous announcements and approvals related to the share buyback plan. The document does not contain financial statements or detailed financial analysis but focuses on the update of the share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2026-01-05 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.